Raseglurant

Raseglurant (ADX-10059) is a selective negative allosteric modulator of the mGlu5 receptor. It has demonstrated efficacy in preclinical models for migraine and has been shown to reduce haloperidol-induced catalepsy in murine studies, supporting research in neuroscience and neuropharmacology.